Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents()

OBJECTIVES: Molnupiravir and nirmatrelvir/ritonavir each became available in the United States (US) through the Food and Drug Administration (FDA) emergency use authorization (EUA) in December 2021 after their respective initial prospective randomized controlled trials demonstrated efficacy for pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gentry, Chris A., Nguyen, Phoi, Thind, Sharanjeet K., Kurdgelashvili, George, Williams, Riley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870610/
https://www.ncbi.nlm.nih.gov/pubmed/36702309
http://dx.doi.org/10.1016/j.jinf.2023.01.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870610/
https://www.ncbi.nlm.nih.gov/pubmed/36702309
http://dx.doi.org/10.1016/j.jinf.2023.01.018

Ejemplares similares